Beijing Minhai Biotechnology Co., Ltd

This completed Phase 3 trial tested a new Sabin strain inactivated polio vaccine (sIPV) in 1200 healthy infants aged 2 months. The study compared the new vaccine to a standard polio vaccine to see if it was safe and triggered a strong immune response. The goal is to offer a more …